Terms: = Bone cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Treatment
355 results:
1. The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol.
Banu MA; Raza SM; Amini M; Seaman S; Rubino F; Snyder R; Patel S; DeMonte F; Conley AP
Neurosurg Focus; 2024 May; 56(5):E15. PubMed ID: 38691867
[TBL] [Abstract] [Full Text] [Related]
2. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
Rujirachaivej P; Siriboonpiputtana T; Luangwattananun P; Yuti P; Wutti-In Y; Choomee K; Sujjitjoon J; Chareonsirisuthigul T; Rerkamnuaychoke B; Junking M; Yenchitsomanus PT
Clin Exp Med; 2024 Apr; 24(1):90. PubMed ID: 38683232
[TBL] [Abstract] [Full Text] [Related]
3. Travel burdens to access care among children with cancer between 2016 and 2019: Analysis of a national population-based cancer registry in Japan.
Tsutsui A; Murakami Y; Okamura S; Fujimaki T; Endo M; Ohno Y
PLoS One; 2024; 19(4):e0300840. PubMed ID: 38625911
[TBL] [Abstract] [Full Text] [Related]
4. [CHIMERIC ANTIGEN RECEPTOR T CELLS (car-T CELLS) THERAPY FOR B-CELL HEMATOLOGICAL MALIGNANCIES - FROM THE ISRAELI SOCIETY OF HEMATOLOGY AND TRANSFUSION MEDICINE].
Greenbaum U; Yehudai-Ofir D; Beyar Katz O; Shargian L; Jacoby E; Grisaru S; Zuckerman T; Ram R; Avigdor A
Harefuah; 2024 Apr; 163(4):236-243. PubMed ID: 38616634
[TBL] [Abstract] [Full Text] [Related]
5. Class I HDAC inhibitors enhance antitumor efficacy and persistence of car-T cells by activation of the Wnt pathway.
Zhu M; Han Y; Gu T; Wang R; Si X; Kong D; Zhao P; Wang X; Li J; Zhai X; Yu Z; Lu H; Li J; Huang H; Qian P
Cell Rep; 2024 Apr; 43(4):114065. PubMed ID: 38578828
[TBL] [Abstract] [Full Text] [Related]
6. A high-content screen of FDA approved drugs to enhance car T cell function: ingenol-3-angelate improves B7-H3-car T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation.
Lee HW; O'Reilly C; Beckett AN; Currier DG; Chen T; DeRenzo C
J Exp Clin Cancer Res; 2024 Apr; 43(1):97. PubMed ID: 38561833
[TBL] [Abstract] [Full Text] [Related]
7. TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers.
Nichakawade TD; Ge J; Mog BJ; Lee BS; Pearlman AH; Hwang MS; DiNapoli SR; Wyhs N; Marcou N; Glavaris S; Konig MF; Gabelli SB; Watson E; Sterling C; Wagner-Johnston N; Rozati S; Swinnen L; Fuchs E; Pardoll DM; Gabrielson K; Papadopoulos N; Bettegowda C; Kinzler KW; Zhou S; Sur S; Vogelstein B; Paul S
Nature; 2024 Apr; 628(8007):416-423. PubMed ID: 38538786
[TBL] [Abstract] [Full Text] [Related]
8. Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus.
Doglio M; Ugolini A; Bercher-Brayer C; Camisa B; Toma C; Norata R; Del Rosso S; Greco R; Ciceri F; Sanvito F; Casucci M; Manfredi AA; Bonini C
Nat Commun; 2024 Mar; 15(1):2542. PubMed ID: 38538608
[TBL] [Abstract] [Full Text] [Related]
9. Locoregional delivery of IL-13Rα2-targeting car-T cells in recurrent high-grade glioma: a phase 1 trial.
Brown CE; Hibbard JC; Alizadeh D; Blanchard MS; Natri HM; Wang D; Ostberg JR; Aguilar B; Wagner JR; Paul JA; Starr R; Wong RA; Chen W; Shulkin N; Aftabizadeh M; Filippov A; Chaudhry A; Ressler JA; Kilpatrick J; Myers-McNamara P; Chen M; Wang LD; Rockne RC; Georges J; Portnow J; Barish ME; D'Apuzzo M; Banovich NE; Forman SJ; Badie B
Nat Med; 2024 Apr; 30(4):1001-1012. PubMed ID: 38454126
[TBL] [Abstract] [Full Text] [Related]
10. Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review.
Neuendorff NR; Khan A; Ullrich F; Yates S; Devarakonda S; Lin RJ; von Tresckow B; Cordoba R; Artz A; Rosko AE
J Geriatr Oncol; 2024 Apr; 15(3):101734. PubMed ID: 38430810
[TBL] [Abstract] [Full Text] [Related]
11. Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review).
Yu T; Jiang W; Wang Y; Zhou Y; Jiao J; Wu M
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38390935
[TBL] [Abstract] [Full Text] [Related]
12. Bispecific antibodies and car-T cells: dueling immunotherapies for large B-cell lymphomas.
Trabolsi A; Arumov A; Schatz JH
Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
[TBL] [Abstract] [Full Text] [Related]
13. Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely B-cell depleted patients with persistent COVID-19.
Inbar T; Dann EJ; Kerner O; Stern A
Transfusion; 2024 Mar; 64(3):443-448. PubMed ID: 38327238
[TBL] [Abstract] [Full Text] [Related]
14. Manufacturing of primary car-NK cells in an automated system for the treatment of acute myeloid leukemia.
Albinger N; Müller S; Kostyra J; Kuska J; Mertlitz S; Penack O; Zhang C; Möker N; Ullrich E
Bone Marrow Transplant; 2024 Apr; 59(4):489-495. PubMed ID: 38253870
[TBL] [Abstract] [Full Text] [Related]
15. Current status and future challenges of car-T cell therapy for osteosarcoma.
Li S; Zhang H; Shang G
Front Immunol; 2023; 14():1290762. PubMed ID: 38187386
[TBL] [Abstract] [Full Text] [Related]
16. Incipient clonal hematopoiesis is accelerated following CD30.car-T therapy.
Kapadia CD; Rosas G; Thakkar SG; Wu M; Torrano V; Wang T; Grilley BJ; Heslop HE; Ramos CA; Goodell MA; Lulla PD
Cytotherapy; 2024 Mar; 26(3):261-265. PubMed ID: 38149948
[TBL] [Abstract] [Full Text] [Related]
17. Chemical genetic control of cytokine signaling in car-T cells using lenalidomide-controlled membrane-bound degradable IL-7.
Kann MC; Schneider EM; Almazan AJ; Lane IC; Bouffard AA; Supper VM; Takei HN; Tepper A; Leick MB; Larson RC; Ebert BL; Maus MV; Jan M
Leukemia; 2024 Mar; 38(3):590-600. PubMed ID: 38123696
[TBL] [Abstract] [Full Text] [Related]
18. Cyclosporine A-resistant car-T cells mediate antitumour immunity in the presence of allogeneic cells.
Zhang Y; Fang H; Wang G; Yuan G; Dong R; Luo J; Lyu Y; Wang Y; Li P; Zhou C; Yin W; Xiao H; Sun J; Zeng X
Nat Commun; 2023 Dec; 14(1):8491. PubMed ID: 38123592
[TBL] [Abstract] [Full Text] [Related]
19. Therapeutic options for large B-cell lymphoma relapsing after CD19-directed car T-cell therapy.
El Warrak S; Kharfan-Dabaja MA; Iqbal M; Hamadani M; Chavez J; Mohty R
Bone Marrow Transplant; 2024 Feb; 59(2):162-170. PubMed ID: 38102213
[TBL] [Abstract] [Full Text] [Related]
20. LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for car T-cell Therapy.
Mai S; Hodges A; Chen HM; Zhang J; Wang YL; Liu Y; Nakatsu F; Wang X; Fang J; Xu Y; Davidov V; Kang K; Pingali SR; Ganguly S; Suzuki M; Konopleva M; Prinzing B; Zu Y; Gottschalk S; Lu Y; Chen SH; Pan PY
Cancer Res; 2023 Dec; 83(24):4047-4062. PubMed ID: 38098451
[TBL] [Abstract] [Full Text] [Related]
[Next]
